Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Attenuated ATO + Low-Dose ATRA in APL
NCT05497310Phase 2Unknown
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Start
- Jul 2022
- Primary completion
- Jun 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide, tretinoin in acute promyelocytic leukemia (APL), sponsored by Hospital Universitario Dr. Jose E. Gonzalez. Status: unknown.
02
Drugs
arsenic trioxidetretinoin
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT05497310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05497310.